Patients treated with adalimumab (ADL) can induce anti-ADL antibodies (AAA) formation that is associated with low drug levels and clinical non-response. But, in the majority of the assays, the measurement of AAA is hampered by the presence of the drug itself. In support of immunogenicity assessment in clinical samples with subtherapeutic ADL levels, we proved acid pre-treatment for AAA detection with the Promonitor-enzyme-linked immunosorbent assay (ELISA). Were measured AAA after acidification in 32 serum samples with a subtherapeutic ADL trough level. ADL and AAA concentrations were measured by ELISA (Promonitor). The impact of drug concentration on AAA recovery (with or without acidification) was also evaluated by mixing known amounts of ADL (0.25, 0.5 and 1 mg/L) and AAA (100, 200, 300 and 400 AU/mL) from clinical samples in pooled serum. The drug significantly inhibited the detection of AAA in untreated samples. And progressively higher levels of ADL cause increasing inhibition of signal. Acid pre-treatment carried a significant increase in assay response, particularly at lower free ADL concentrations. AAA were detected in the 53 % of the samples after acid dissociation. In seven patients, the positive AAA after dissociation was detected in the first monitoring of ADL and five patients were positive 3 months later for AAA with the standard assay. Monitoring AAA using acid dissociation in patients with subtherapeutic circulating level of ADL could detect precocious problems of bioavailability, assess the immunogenicity of ADL and may be used to optimise dose regimens, thereby preventing prolonged use of inadequate therapy and guide change of treatment.

Duración del tratamiento con etanercept y razones de discontinuación en una cohorte de pacientes con patología reumática.JM Senabre-Gallego1, J Rosas-Gómez1, G Santos-Soler1, C Santos-Ramírez2, X BarberVallés3, M Sánchez-Barrioluengo4, E Salas-Heredia1, C Cano-Pérez5, R Riestra-Juán5, N Llahí-Vidal5.1. Reumatología, Hospital Marina Baixa, Villajoyosa (Alicante).2. Hospital Marina Salud, Denia (Alicante).3. CIO-UMH de Elche (Alicante). INTRODUCCIÓN:La terapia biológica, iniciada con los inhibidores del TNF-α (tumor necrosis factor α) infliximab (INF), adalimumab (ADA) y etanercept (ETN), ha cambiado radicalmente el tratamiento de ciertas enfermedades reumáticas como la artritis reumatoide (AR) o la espondilitis anquilosante (EA). La eficacia de estos fármacos anti-TNF ha sido demostrada en numerosos ensayos clínicos, pero ninguno de los tres es superior a los demás según los metaanálisis existentes y no existen ensayos clínicos comparativos 1 .

No abstract

No abstract

No abstract